Results 81 to 90 of about 181,705 (382)

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

Advanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar, Weiwei Guo, Xin Shen, Yimeng Fang, Yilin Liu, Peng‐Yuan Wang, Roey Elnathan, Yaping Chen   +7 more
wiley   +1 more source

Localised Laryngeal Amyloidosis Endoscopic Excision -A Case Report [PDF]

, 2013
:We report a case of primary laryngeal amyloidosis in a 35 year old adult patient who presented with hoarseness of voice for 6 months duration with no other symptoms.
Sundhar Krishnan, Gurunathan, Varma, Srinivasa, Vikram, Venakata Subramanian Jagannathan   +2 more
core   +1 more source

?2-Microglobulin Amyloid Fibril-Induced Membrane Disruption Is Enhanced by Endosomal Lipids and Acidic pH [PDF]

, 2014
Although the molecular mechanisms underlying the pathology of amyloidoses are not well understood, the interaction between amyloid proteins and cell membranes is thought to play a role in several amyloid diseases. Amyloid fibrils of ?2-microglobulin (?2m)
A Halle, A Ivankin, AD Petelska, AM Smith, B Boland, B Reed, C Cecchi, C Luquain, CJ Sarell, CL Bergstrom, CM Franzin, D Eisenberg, D Freeman, DE Lee, DP Smith, EE Ambroggio, Eric W. Hewitt, F Ferrone, F Gejyo, G van Meer, H Ohvo-Rekila, HD Gallala, HE White, I Benilova, IJ Morten, J Brotheru, J Brotherus, J Pan, J Villanueva, J Zimmerberg, JH Lee, JN Chebukati, JR Wherrett, JW Becker, K Berthelot, K Ditaranto, Kevin W. Tipping, L Milanesi, L Pieri, L Pieri, L Rajendran, M Arrasate, M Bostrom, M Bucciantini, M Duan, M Garcia-Garcia, M Stefani, MF Sciacca, MFM Engel, MFM Sciacca, MP Fogarty, MR Eftink, MY Porter, N Cremades, N Demaurex, N Liguori, Neil A. Ranson, NM Kad, NP Reynolds, Patrick van der Wel, Paul A. Beales, Rebecca Thompson, RF Chen, S Huterer, S Valleix, S Yamamoto, Sheena E. Radford, SL Myers, Sophia C. Goodchild, T Eichner, T Hayakawa, T Kobayashi, T Kobayashi, T Kobayashi, T Kobayashi, T Ookoshi, T Sheynis, T Umeda, Tania Sheynis, TE Frederick, TE Frederick, TL Williams, TL Williams, TP Knowles, TPJ Knowles, TR Jahn, TR Jahn, V Soura, VJ McParland, VN Uversky, Wei-Feng Xue, WF Xue, WF Xue, WF Xue, WF Xue, WF Xue, WG Wood, Y Hirakura, ZS Ji   +98 more
core   +4 more sources

Amyloid Forming Human Lysozyme Intermediates are Stabilized by Non‐Native Amide‐π Interactions

Advanced Science, EarlyView.
Mutational variants of human lysozyme cause fatal systemic amyloidosis by depositing kilograms of protein in the viscera of patients. Central to this process is a partially unfolded protein intermediate state that initiates aggregation into amyloid fibrils.
Minkoo Ahn, Julian O. Streit, Christopher A. Waudby, Tomasz Włodarski, Angelo Miguel Figueiredo, John Christodoulou, Janet R. Kumita   +6 more
wiley   +1 more source

Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery

Aggregate, EarlyView.
This review highlights recent progress in cell membrane‐coated lipid nanoparticles (CMC‐LNPs), focusing on their design, preparation methods, functional integration, and biomedical applications. It discusses various types of LNPs and coating strategies, characterization techniques, therapeutic functions, and applications.
Moataz B. Zewail, Guangze Yang, Yilong Fan, Yue Hui, Chun‐Xia Zhao, Yun Liu   +5 more
wiley   +1 more source

Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis

Haematologica, 2015
Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty may ...
Sajitha Sachchithanantham, Mark Offer, Christopher Venner, Shameem A. Mahmood, Darren Foard, Lisa Rannigan, Thirusha Lane, Julian D. Gillmore, Helen J. Lachmann, Philip N. Hawkins, Ashutosh D. Wechalekar   +10 more
doaj   +1 more source

Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease

Biomedicines, 2022
Orthopaedic manifestations of wild-type transthyretin amyloidosis are frequent and characteristic, including idiopathic bilateral carpal tunnel syndrome, idiopathic lumbar canal stenosis, atraumatic rupture of the brachial biceps tendon, and, more rarely,
Federico Perfetto, Mattia Zampieri, Giulia Bandini, Roberto Fedi, Roberto Tarquini, Raffaella Santi, Luca Novelli, Marco Allinovi, Alessia Argirò, Francesco Cappelli   +9 more
doaj   +1 more source

Multimodal MRI-based Imputation of the Aβ+ in Early Mild Cognitive Impairment. [PDF]

, 2014
ObjectiveTo identify brain atrophy from structural-MRI and cerebral blood flow(CBF) patterns from arterial spin labeling perfusion-MRI that are best predictors of the Aβ-burden, measured as composite 18F-AV45-PET uptake, in individuals with early mild ...
Joshi, Sarang, the Alzheimer’s Disease Neuroimaging Initiative, Tosun, Duygu, Weiner, Michael W   +3 more
core   +1 more source

Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils

Aggregate, EarlyView.
This review addresses the gap between strong evidence for the involvement of amyloid fibrils in neurodegeneration and the failure of anti‐amyloid therapies, a phenomenon herein termed the “amyloid paradox.” To address this paradox, we provide a comprehensive summary of the current understanding of fibrils' pathogenic properties and mechanisms ...
Maksim I. Sulatsky, Olesya V. Stepanenko, Olga V. Stepanenko, Anna I. Sulatskaya   +3 more
wiley   +1 more source

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

Neurological Therapeutics, 2020
Hereditary variant transthyretin amyloidosis (ATTRv) is a rare genetic defect that affects about 5000–10,000 people worldwide, causing amyloidosis secondary to misfolding of mutant transthyretin (TTR) protein fibrils.
Ivan Urits, Daniel Swanson, Michael C Swett, Anjana Patel, Kevin Berardino, Ariunzaya Amgalan, A. Berger, Hisham Kassem, A. Kaye, Omar Viswanath   +9 more
semanticscholar   +1 more source